Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
206.36B
Market cap206.36B
Price-Earnings ratio
11.32
Price-Earnings ratio11.32
Dividend yield
2.65%
Dividend yield2.65%
Average volume
17.18M
Average volume17.18M
High today
$46.11
High today$46.11
Low today
$45.50
Low today$45.50
Open price
$45.98
Open price$45.98
Volume
5.80M
Volume5.80M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

The Motley Fool 1h
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

Novo Nordisk (NVO -0.91%) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the compan...

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
TipRanks 2h
Novo Nordisk Completes Key Oral Semaglutide Study in Japan: What Investors Should Watch

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

TipRanks 2h
Novo Nordisk’s SEMA-CardioDiab Hungary Study: What Real-World Oral Semaglutide Data Could Mean for NVO Investors

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Analyst ratings

57%

of 37 ratings
Buy
35.1%
Hold
56.8%
Sell
8.1%

More NVO News

The Motley Fool 2h
Lexicon Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and Director - Mike Exton Senior Vice President...

Lexicon Q2 2026 Earnings Call Transcript
Seeking Alpha 3h
Novo Nordisk CEO Doustdar says obesity drugs market won't be dominated by one player

Novo Nordisk (NVO) CEO Mike Doustdar believes that the market for obesity drugs won't end up in a winner-takes-all battle as consumers are searching for options...

Novo Nordisk CEO Doustdar says obesity drugs market won't be dominated by one player
TipRanks 3h
Novo Nordisk CEO Defends Lawsuit Against Eli Lilly

Novo Nordisk (NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly (LLY) over what it alleges is false advertising...

24/7 Wall St. 5h
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover By Trey Thoelcke Published Aug 13, 9:05AM EDT Quick Read WVE sits 69% below its...

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
TipRanks 5h
Novo Nordisk Stock Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly

Shares in Danish drugmaker Novo Nordisk (NVO) fell about 2% to roughly $46 per share early Thursday. The decline came even though CEO Mike Doustar told Reuters...

CNBC 18h
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer - CNBC

...

Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer - CNBC
Simply Wall St 22h
Novo Nordisk Stock Still Looks Cheap On Earnings But Faces Growth Doubts

Novo Nordisk stock has pulled back sharply over the last three years, yet the company still screens as attractively valued on several checks. Recent news on obe...

Novo Nordisk Stock Still Looks Cheap On Earnings But Faces Growth Doubts

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.